U.S. Markets closed

AC Immune SA (ACIU)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
8.89-0.09 (-1.00%)
At close: 4:00PM EDT

8.89 0.00 (0.00%)
After hours: 4:00PM EDT

Sign in to post a message.
  • W
    WealthMastersClub1
    AC Immune - Pioneering precision medicine for neurodegenerative diseases

    1. Significant market potential for Alzheimer's disease (AD) and other neurodegenerative diseases
    >>> Broadest pipeline in the field addressing Tau, Abeta, a-syn, TDP-43 and neuro inflammation

    2. Highly differentiated precision medicine approach
    >>> Dual clinically validated platforms generate First/Best-in-Class therapeutics and diagnostics

    3. Most comprehensive portfolio of candidates targeting Tau at key points in disease pathway
    >>> Clinical-stage antibody, vaccine, small molecule inhibitor and diagnostic imaging agent

    4. Multiple clinical catalysts anticipated in 2020 to drive near term value inflection
    >>> Key upcoming data readouts: Abeta vaccine (Phase 1b, DS and Phase 2, AD);
    Tau small molecule (Phase 1); Tau PET tracer (Phase 1, PSP)

    5. Marquis partnerships with leading global pharma companies
    >>> Secured CHF 334 million to date in non-dilutive funding with >CHF 3 billion in potential
    milestone payments plus royalties

    6. Experienced management with strong tract record of developing and out-licensing assets
    Bullish
  • T
    Thanos-a-diol
    Zacks articlee....provocative..." Investors in AC Immune SA ACIU need to pay close attention to the stock based on moves in the options market lately. That is because the Sep 18, 2020 $12.50 Call had some of the highest implied volatility of all equity options today.".....which means they expect high demand for the options, cause implicitly by share price being substantially over 12.50$. But question is what is the fundamental speculation? Pre COVID19, I think the Eli Lily milestone (Tau morphomer) for 60 million francs for starting P2 may be on the horizon (once P1 reported and some time for pre a)pprovals. So just possibly there is speculation for speculation of big block share purchases over the horizon for Tau program.
  • A
    Anonymous
    just a thought experiment:

    biogen‘s market cap fluctuates around +/- 30% when adacunumab‘s ups and downs and ups were communicated. this is about 15 billions.

    assuming aciu has any good phase 2 data for AD and we take 10% of those 15 bn (10% as it’s only phase 2, & partnered with roche / janssen / eli ) we should add at least 1.5bn of market cap, which would result in 200-300% share price increase.

    i‘d like that!
    Neutral
  • W
    WealthMastersClub1
    AC Immune to Showcase Anti-Tau Portfolio at H.C. Wainwright 22nd Annual Global Investment ConferenceH.C. Wainwright 22nd Annual Global Investment Conference

    Date: September 15, 2020 | 10:00–10:20 am ET / 4:00–4:20 pm CET
    Format: Virtual Presentation followed by Q&A
    Presenter: Prof. Andrea Pfeifer, CEO, AC Immune SA
  • W
    WealthMastersClub1
    Just got this on my radar and we decided to buy. With such robust and impressive pipeline in neurodegenerative diseases therapy/treatment backed with leading top notch Pharma partnerships. This is a no brainer in its class!
    I can't believed this is trading this low. ACIU IPO'd at $11 four years ago and was trading as high as $25 at some point. This stock is way undervalued, in my opinion. Going long term here!
    Bullish
  • W
    WealthMastersClub1
    Nicely accumulated leading to upcoming clinical readouts.
    Bullish
  • E
    EDWARD
    8/21/20 9:14 am EST: AC Immune upcoming readout risk-reward skews positive, says SVB Leerink 09:14 ACIU SVB Leerink analyst Marc Goodman maintained an Outperform rating and $13 price target on AC Immune ahead of the upcoming data readout for the company's semorinemab Phase 2 study, TAURIEL, in treating prodromal-to-mild Alzheimer's disease in the second half of 2020. The analyst likes the risk/reward of the readout, as he expects limited downside of around 10% with a negative trial, but a 45%-50% move upward with a positive trial.

    Read more at:
    https://thefly.com/n.php?id=3149883
    AC Immune upcoming readout risk-reward skews positive, says SVB Leerink SVB Leerink ACIU
    AC Immune upcoming readout risk-reward skews positive, says SVB Leerink SVB Leerink ACIU
    thefly.com
    Bullish
  • T
    Thanos-a-diol
    Being fully funded through 2024 is amazing for an actively researching biotech/pharmaceuticals company
  • T
    Thanos-a-diol
    With a high of another 2 pct, I would say the AC IMMUNE presentation is nicely received by the investing community and still "digesting". I think we will see a delayed positive response in the coming month to presentation.
  • J
    John
    You either didn't read the article in it's entirety or you don't understand the concept of "open interest." Open interest can represent calls bought or sold, or both. Based on the open interest and the premium associated with the $12.50 call, more likely the open interest was nothing more than somebody(s) sold the calls and banked the premium. Tomorrow morning, unless there's some significant news event for ACIU, the $12.50 calls will become worthless at the open if they're not already. Good for whomever sold the calls! Great trade.
    Neutral
  • Y
    Yahoo Finance Insights
    AC Immune is up 8.22% to 8.43
  • T
    Thanos-a-diol
    NEWS flash is that BIOGEN Aducanumab BLA was accepted and expedited to priority review PDUFA date will be around March 2021. This is big news for Az research and may put stymie on some price growth for ACIU, but remember FDA does not generally play fair even after setting dates. It is big news for Abeta treatments.
  • T
    Thanos-a-diol
    When you see large swings in price, relatively low volume, then you know something big is happening. Big players shaking the tree, as it was before RH.
  • m
    mike
    Why did this company spike substantially for about a half hour trading of one day then drop like a rock to below what it was before Biogen ACTED like they were interested in their products? Hmmm. Let me know what you think and I’ll drop another, here a little later with the real reason...Feel free to drop any comments on your opinion for this huge pop and then bigger drop.
  • C
    Claud
    Anyone see any news? I have not been able to find any.
  • A
    Atehortua
    Gapping up on news they are advancing to phase 1b/2a study on Alzheimer Vaccine. Watching for $8.10 to hold on any pullback and watching for a push to test $14.32 We are trading $ACIU come join us https://daytrading.group/v6ff7
    True Trading Group Home Page - True Trading Group
    daytrading.group
  • K
    Keri
    ACIU appears to be one of the key movers following its announcement to shift a higher dosing group to its Alzheimer's disease treatment. It appears trade volume moves more than 400% relative to its daily average at this time. Also, a potentially massive boom in this sector could emerge from a potential listing of cryptocurrency assets on one of the global payments giant platforms. http://psce.pw/DisruptingaMultiTrillionIndustryHotStocks
    “According to McKinsey, the Global Payments industry is a $1.9 trillion-dollar industry.
    “According to McKinsey, the Global Payments industry is a $1.9 trillion-dollar industry.
    psce.pw
    Bullish
  • m
    mike
    The reason AC immune SA popped for a half hour last week and now it’s dropped below what it was before the pop... There’s really no such thing as a vaccine for Alzheimer's. Corrupt big Pharm Biogen put a carrot in front of this company And if you bought this ACIU bull Sheet you are not smart investors, buying in high and now they’re all bag holders at around $12 purchase PPS.

    The only company with a 2b FDA stage treatment for Alzheimer's as well as an early stage simple blood test for diagnosis is cassava sciences SAVA. You can All make your own investment decisions although I would recommend taking all your money from this company and Biogen and moving it all over to cassava sciences. You’ll be greatly rewarded believe me...or not! I’ll comment further on this one in about a month.
  • W
    Weary Nant Holder
    I dont get the 7 seller. this is too easy hold.
    Bullish
  • M
    Monstoyo
    Will this close above or below 10 today?